Top

BMC Geriatrics

Published in:

Open Access 01-12-2023 | Dementia | Research

Dementia subtypes, cognitive decline and survival among older adults attending a memory clinic in Cape Town, South Africa: a retrospective study

Authors: Michael Ssonko, Anneli Hardy, Vasi Naganathan, Sebastiana Kalula, Marc Combrinck

Published in: BMC Geriatrics | Issue 1/2023

Abstract

Background

There are no published longitudinal studies from Africa of people with dementia seen in memory clinics. The aim of this study was to determine the proportions of the different dementia subtypes, rates of cognitive decline, and predictors of survival in patients diagnosed with dementia and seen in a memory clinic.

Methods

Data were collected retrospectively from clinic records of patients aged ≥ 60 seen in the memory clinic at Groote Schuur Hospital, Cape Town, South Africa over a 10-year period. Diagnostic and Statistical Manual of Mental Disorders (DSM–5) criteria were used to identify patients with Major Neurocognitive Disorders (dementia). Additional diagnostic criteria were used to determine the specific subtypes of dementia. Linear regression analysis was used to determine crude rates of cognitive decline, expressed as mini-mental state examination (MMSE) points lost per year. Changes in MMSE scores were derived using mixed effects modelling to curvilinear models of cognitive change, with time as the dependent variable. Multivariable cox survival analysis was used to determine factors at baseline that predicted mortality.

Results

Of the 165 patients who met inclusion criteria, 117(70.9%) had Major Neurocognitive Disorder due to Alzheimer’s disease (AD), 24(14.6%) Vascular Neurocognitive Disorder (VND), 6(3.6%) Dementia with Lewy Bodies (DLB), 5(3%) Parkinson disease-associated dementia (PDD), 3(1.8%) fronto-temporal dementia, 4(2.4%) mixed dementia and 6(3.6%) other types of dementia. The average annual decline in MMSE points was 2.2(DLB/PDD), 2.1(AD) and 1.3(VND). Cognitive scores at baseline were significantly lower in patients with 8 compared to 13 years of education and in those with VND compared with AD. Factors associated with shorter survival included age at onset greater than 65 (HR = 1.82, 95% C.I. 1.11, 2.99, p = 0.017), lower baseline MMSE (HR = 1.05, 95% C.I. 1.01, 1.10, p = 0.029), Charlson’s comorbidity scores of 3 to 4 (HR = 1.88, 95% C.I. 1.14, 3.10, p = 0.014), scores of 5 or more (HR = 1.97, 95% C.I. 1.16, 3.34, p = 0.012) and DLB/PDD (HR = 3.07, 95% C.I. 1.50, 6.29, p = 0.002). Being female (HR = 0.59, 95% C.I.0.36, 0.95, p = 0.029) was associated with longer survival.

Conclusions

Knowledge of dementia subtypes, the rate and factors affecting cognitive decline and survival outcomes will help inform decisions about patient selection for potential future therapies and for planning dementia services in resource-poor settings.

Available only for authorised users

Lekoubou A, Echouffo-Tcheugui JB, Kengne AP. Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review. BMC Public Health. 2014;14:653.CrossRefPubMed

Kalula SZ, Ferreira M, Thomas KG, de Villiers L, Joska JA, Geffen LN. Profile and management of patients at a memory clinic. S Afr Med J. 2010;100(7):449–51.CrossRefPubMed

Ndiaye NND, Sylla A, Toure K, Thiam MH, Gueye M. Operations assessment in a senegalese memory clinic, Fann Teaching Hospital Psychiatric Department (Dakar, Senegal). Afr J Neurol Sci. 2011;30:2–10.

Amoo G, Akinyemi RO, Onofa LU, Akinyemi JO, Baiyewu O, Ogunlesi AO, Ogunniyi A. Profile of clinically-diagnosed dementias in a neuropsychiatric practice in Abeokuta, south-western Nigeria. Afr J Psychiatry (Johannesbg). 2011;14(5):377–82.PubMed

Chow TW, Hynan LS, Lipton AM. MMSE scores decline at a greater rate in frontotemporal degeneration than in AD. Dement Geriatr Cogn Disord. 2006;22(3):194–9.CrossRefPubMed

Kramberger MG, Auestad B, Garcia-Ptacek S, Abdelnour C, Olmo JG, Walker Z, Lemstra AW, Londos E, Blanc F, Bonanni L, et al. Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter. International Cohort J Alzheimers Dis. 2017;57(3):787–95.CrossRefPubMed

Oh ES, Lee JH, Jeong SH, Sohn EH, Lee AY. Comparisons of cognitive deterioration rates by dementia subtype. Arch Gerontol Geriatr. 2011;53(3):320–2.CrossRefPubMed

Arce Rentería M, Vonk JMJ, Felix G, Avila JF, Zahodne LB, Dalchand E, Frazer KM, Martinez MN, Shouel HL, Manly JJ. Illiteracy, dementia risk, and cognitive trajectories among older adults with low education. Neurology. 2019;93(24):e2247–56.PubMedCentralCrossRefPubMed

Stanley K, Whitfield T, Kuchenbaecker K, Sanders O, Stevens T, Walker Z. Rate of cognitive decline in Alzheimer’s disease stratified by age. J Alzheimers Dis. 2019;69(4):1153–60.CrossRef

10.

Sakurai H, Hanyu H, Sato T, Kanetaka H, Shimizu S, Hirao K, Kikukawa M, Iwamoto T. Vascular risk factors and progression in Alzheimer’s disease. Geriatr Gerontol Int. 2011;11(2):211–4.CrossRefPubMed

11.

Gerritsen AAJ, Bakker C, Verhey FRJ, Bor H, Pijnenburg YAL, de Vugt ME, Koopmans R. The progression of dementia and cognitive decline in a Dutch 2-year cohort study of people with young-onset dementia. J Alzheimers Dis. 2018;63(1):343–51.CrossRefPubMed

12.

Hui JS, Wilson RS, Bennett DA, Bienias JL, Gilley DW, Evans DA. Rate of cognitive decline and mortality in Alzheimer’s disease. Neurology. 2003;61(10):1356–61.CrossRefPubMed

13.

Rascovsky K, Salmon DP, Lipton AM, Leverenz JB, DeCarli C, Jagust WJ, Clark CM, Mendez MF, Tang-Wai DF, Graff-Radford NR, Galasko D. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology. 2005;65(3):397–403.CrossRefPubMed

14.

Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, Thal LJ. Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology. 1998;51(2):351–7.CrossRefPubMed

15.

Garcia-Ptacek S, Farahmand B, Kåreholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41(2):467–77.CrossRefPubMed

16.

Ientile L, De Pasquale R, Monacelli F, Odetti P, Traverso N, Cammarata S, Tabaton M, Dijk B. Survival rate in patients affected by dementia followed by memory clinics (UVA) in Italy. J Alzheimers Dis. 2013;36(2):303–9.CrossRefPubMed

17.

Connors MH, Ames D, Boundy K, Clarnette R, Kurrle S, Mander A, Ward J, Woodward M, Brodaty H. Predictors of mortality in dementia: the PRIME study. J Alzheimers Dis. 2016;52(3):967–74.CrossRefPubMed

18.

Garre-Olmo J, Ponjoan A, Inoriza JM, Blanch J, Sánchez-Pérez I, Cubí R, de Eugenio R, Turró-Garriga O, Vilalta-Franch J. Survival, effect measures, and impact numbers after dementia diagnosis: a matched cohort study. Clin Epidemiol. 2019;11:525–42.CrossRefPubMed

19.

Gerritsen AAJ, Bakker C, Verhey FRJ, Pijnenburg YAL, Millenaar JK, de Vugt ME, Koopmans R. Survival and life-expectancy in a young-onset dementia cohort with six years of follow-up: the NeedYD-study. Int Psychogeriatr. 2019;31(12):1781–9.CrossRefPubMed

20.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44.CrossRefPubMed

21.

Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43(2):250–260.

22.

McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Arch Neurol. 2001;58(11):1803–9.CrossRefPubMed

23.

McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113–24.CrossRefPubMed

24.

Barton B, Grabli D, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson’s disease with dementia. Mov Disord. 2012;27(2):248–53.CrossRefPubMed

25.

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22(12):1689–1707; quiz 1837.

26.

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed

27.

StataCorp L: Stata statistical software: Release 17 College Station: StataCorp LLC 2021.

28.

Sheng B, Law CB, Yeung KM. Characteristics and diagnostic profile of patients seeking dementia care in a memory clinic in Hong Kong. Int Psychogeriatr. 2009;21(2):392–400.CrossRefPubMed

29.

Alladi S, Mekala S, Chadalawada SK, Jala S, Mridula R, Kaul S. Subtypes of dementia: a study from a memory clinic in India. Dement Geriatr Cogn Disord. 2011;32(1):32–8.CrossRefPubMed

30.

Bickel H, Bürger K, Hampel H, Schreiber Y, Sonntag A, Wiegele B, Förstl H, Kurz A. Presenile dementia in memory clinics–incidence rates and clinical features. Nervenarzt. 2006;77(9):1079–85.CrossRef

31.

Slot RE, Sikkes SA, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA. Subjective cognitive decline and rates of incident Alzheimer’s disease and non–Alzheimer’s disease dementia. Alzheimers Dement. 2019;15(3):465–76.CrossRef

32.

Picard C, Pasquier F, Martinaud O, Hannequin D, Godefroy O. Early onset dementia: characteristics in a large cohort from academic memory clinics. Alzheimer Dis Assoc Disord. 2011;25(3):203–5.CrossRefPubMed

33.

Gan J, Liu S, Wang X, Shi Z, Shen L, Li X, Guo Q, Yuan J, Zhang N, You Y. Clinical characteristics of Lewy body dementia in Chinese memory clinics. BMC Neurol. 2021;21(1):1–11.CrossRef

34.

Cattel C, Gambassi G, Sgadari A, Zuccala G, Carbonin P, Bernabei R. Correlates of delayed referral for the diagnosis of dementia in an outpatient population. J Gerontol A Biol Sci Med Sci. 2000;55(2):M98-102.CrossRef

35.

Ng NSQ, Ward SA. Diagnosis of dementia in Australia: a narrative review of services and models of care. Aust Health Rev. 2018;43(4):415–24.CrossRef

36.

Jia J, Zuo X, Jia XF, Chu C, Wu L, Zhou A, Wei C, Tang Y, Li D, Qin W. Diagnosis and treatment of dementia in neurology outpatient departments of general hospitals in China. Alzheimers Dement. 2016;12(4):446–53.CrossRefPubMed

37.

Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic-vs community-based cohorts. Arch Neurol. 2009;66(9):1151–7.PubMedCentralCrossRef

38.

Koedam EL, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YA. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401–8.CrossRefPubMed

39.

Fereshtehnejad SM, Lökk J, Wimo A, Eriksdotter M. No significant difference in cognitive decline and mortality between Parkinson’s disease dementia and dementia with Lewy bodies: naturalistic longitudinal data from the Swedish dementia registry. J Parkinsons Dis. 2018;8(4):553–61.CrossRefPubMed

40.

Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different? Parkinsonism Relat Disord. 2005;11:S47–51.CrossRef

41.

Canevelli M, Kelaiditi E, Del Campo N, Bruno G, Vellas B, Cesari M. Predicting the rate of cognitive decline in Alzheimer disease: data from the ICTUS study. Alzheimer Dis Assoc Disord. 2016;30(3):237–42.CrossRefPubMed

42.

Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology. 2005;64(12):2069–73.CrossRef

43.

Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol. 2003;106(4):374–82.CrossRefPubMed

44.

Pilon MH, Poulin S, Fortin MP, Houde M, Verret L, Bouchard RW, Laforce R. Differences in rate of cognitive decline and caregiver burden between Alzheimer’s disease and vascular dementia: a retrospective study. Neurology (ECronicon). 2016;2(6):278–86.PubMed

45.

Dong Y, Sharma VK. Chan BP-L, Venketasubramanian N, Teoh HL, Seet RCS, Tanicala S, Chan YH, Chen C. The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci. 2010;299(1–2):15–8.

46.

Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA. 1993;269(18):2386–91.CrossRef

47.

Iyer GK, Alladi S, Bak TH, Shailaja M, Mamidipudi A, Rajan A, Gollahalli D, Chaudhuri JR, Kaul S. Dementia in developing countries: does education play the same role in India as in the West? Dementia & Neuropsychologia. 2014;8(2):132–40.CrossRef

48.

O’Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, Lucas JA. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol. 2008;65(7):963–7.PubMed

49.

https://www.westerncape.gov.za/text/2005/12/11_soer_education_optimised_05.pdf. (Accessed 12 Oct 2023):91.

50.

Hanyu H, Sato T, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Differences in clinical course between dementia with Lewy bodies and Alzheimer’s disease. Eur J Neurol. 2009;16(2):212–7.CrossRefPubMed

51.

Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935–41.CrossRefPubMed

52.

Loi SM, Tsoukra P, Chen Z, Wibawa P, Mijuskovic T, Eratne D, Di Biase MA, Evans A, Farrand S, Kelso W, et al. Mortality in dementia is predicted by older age of onset and cognitive presentation. Aust N Z J Psychiatry. 2021:48674211041003.

53.

Ferrucci L, Gonzalez-Freire M, Fabbri E, Simonsick E, Tanaka T, Moore Z, Salimi S, Sierra F, de Cabo R. Measuring biological aging in humans: a quest. Aging Cell. 2020;19(2).CrossRefPubMed

54.

Foguem C, Kamsu-Foguem B. Neurodegeneration in tauopathies and synucleinopathies. Rev Neurol (Paris). 2016;172(11):709–14.CrossRefPubMed

55.

Brodaty H, Woodward M, Boundy K, Ames D, Balshaw R. Patients in Australian memory clinics: baseline characteristics and predictors of decline at six months. Int Psychogeriatr. 2011;23(7):1086–96.CrossRefPubMed

56.

Cullum S, Varghese C, Coomarasamy C, Whittington R, Hadfield L, Rajay A, Yeom B, Liu B, Christie M, Appleton K, et al. Predictors of mortality in Māori, Pacific Island, and European patients diagnosed with dementia at a New Zealand Memory Service. Int J Geriatr Psychiatry. 2020;35(5):516–24.CrossRefPubMed

57.

Haaksma ML, Eriksdotter M, Rizzuto D. Leoutsakos J-MS, Rikkert MGO, Melis RJ, Garcia-Ptacek S: Survival time tool to guide care planning in people with dementia. Neurology. 2020;94(5):e538–48.CrossRefPubMed

58.

Aubert L, Pichierri S, Hommet C, Camus V, Berrut G, de Decker L. Association between comorbidity burden and rapid cognitive decline in individuals with mild to moderate Alzheimer’s disease. J Am Geriatr Soc. 2015;63(3):543–7.CrossRefPubMed

59.

Fischer CE, Jiang D, Schweizer TA. Determining the association of medical co-morbidity with subjective and objective cognitive performance in an inner city memory disorders clinic: a retrospective chart review. BMC Geriatr. 2010;10:89.PubMedCentralCrossRefPubMed

60.

Magaki S, Yong WH, Khanlou N, Tung S, Vinters HV. Comorbidity in dementia: update of an ongoing autopsy study. J Am Geriatr Soc. 2014;62(9):1722–8.PubMedCentralCrossRefPubMed

61.

Zhang Y-Q, Wang C-F, Xu G, Zhao Q-H, Xie X-Y, Cui H-L, Wang Y, Ren R-J, Guo Q-H, Wang G. Mortality of Alzheimer’s disease patients: a 10-year follow-up pilot study in Shanghai. Can J Neurol Sci. 2020;47(2):226–30.CrossRefPubMed

62.

Hogervorst E, Barnetson L, Jobst K, Nagy Z, Combrinck M, Smith A. Diagnosing dementia: interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000;11(2):107–13.CrossRefPubMed

Title: Dementia subtypes, cognitive decline and survival among older adults attending a memory clinic in Cape Town, South Africa: a retrospective study
Authors: Michael Ssonko
Anneli Hardy
Vasi Naganathan
Sebastiana Kalula
Marc Combrinck
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Dementia
Dementia
Alzheimer's Disease
Alzheimer's Disease
Published in: BMC Geriatrics / Issue 1/2023
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-023-04536-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Re-examination of successful agers with lower biological than chronological age still after a 20-year follow-up period

Effects of dance therapy on cognitive and mental health in adults aged 55 years and older with mild cognitive impairment: a systematic review and meta-analysis

Predicting mortality in patients diagnosed with advanced dementia presenting at an acute care hospital: the PROgnostic Model for Advanced DEmentia (PRO-MADE)

Study protocol for ELders AT Ease (ELATE): a cluster randomised controlled trial of cognitive behaviour therapy to reduce depressive symptoms in aged care residents

Genetic and environmental influences on fruit and vegetable consumption and depression in older adults

Prevalence of frailty in Indonesia: a systematic review and meta-analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials